For BRAF V600E mutant NSCLC, acquired resistance after dabrafenib monotherapy is caused by oncogenic KRAS mutations and subsequent sustained BRAF non-dependent MEK activation (156). This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.